ALHCAlignment Healthcare, Inc.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though modest expectations priced in.
Priced for a decline (~−4% a year). The price demands less than its three-year revenue growth of 41% a year, expectations look modest.
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ALHC's price assumes
Alignment Healthcare, Inc. trades at 42.5× earnings against 25.7× for the median Healthcare Plans name, more expensive than its own group.
Trailing P/E · Healthcare Plans median 25.7 · 1.65× the median: the market pays up for this one
- Price / sales
- 0.37
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 11%
Free cash flow yield · Healthcare Plans median 7.4%
- Growth the price implies
- −4.4%
Growth the price implies · The price pays for −4.4% free cash flow growth a year for a decade; the business has delivered +57% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 6.32
- EV / EBIToperating margin 1.2%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 0.28
- Healthcare median P/E503 names
- 27.9
- Healthcare Plans median P/E11 names
- 25.7
- Free cash flow, trailing twelve months
- $178M
- Market capitalisation207.4 million shares, counted Jul 27, 2026
- $1.68B
- 3-year revenue growth
- +41%
- 3-year free cash flow growth
- +57%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.